Biomedtech About

Kalios™, an adjustable ring to repair the mitral valve by Affluent Medical

Kalios™, developed by Affluent Medical, is the first mitral annuloplasty device that can be percutaneously adjusted to optimize valve repair at any time after implant, repeatedly, and while the heart is beating, thus avoiding the need for further surgery.

Epygon, an artificial minimally invasive valve that mimics the human valve

Epygon, developed by Affluent Medical, is the first “physiological” transcatheter mitral prosthesis; it can restore the natural blood flow vortex in the left ventricle, thereby fostering recovery of ventricular function, especially in fragile patients with a seriously impaired cardiac condition.

Artus, the first artificial sphincter that is adjustable and easy to live with

Artus, developed by Affluent Medical, is the first remotely controlled solution for stress urinary incontinence in both men and women implanted by a 30 minute minimally invasive procedure.

For 25 years, Truffle Capital has been driving innovation and creating technology leaders in Biotech, MedTech, and BioEcoTech, focusing on radical innovations and interventional medicine to create groundbreaking companies. Collaborating closely with the world's top research centers, Truffle Capital transforms significant unmet needs into major technological advancements, novel medical devices, and effective drug treatments. Through its fund MEDEOR, Truffle Capital invests in clinical-stage therapeutic device companies across Europe.

Truffle BioMedTech: Over 20 Years of Radical Innovation

33

Companies backed since 2001

19

Exclusive In-License Technologies from Academics

17M

Patients annually could benefit from these innovative solutions

€278M

AuM

€2.4Bn

Raised in equity by Truffle’s BioMedTech companies

>€250M

Granted in non-dilutive fundings

_otr8874.jpg

"We are looking for technologies that are going to revolutionize their therapeutic areas. We are not focused on marginal innovations, We are only sourcing radical innovations."

"We either create new companies from patent applications, or we strengthen existing companies, in the European Ecosystem"

"There is no major problem or issue that great science and R&D cannot address"

Philippe Pouletty, M.D.

CEO & Co-founder, BioMedTech

SELECTION OF OUR SUCCESSES

LATEST NEWS